MCL remission duration doubles with rituximab
Tuesday 2 August 2011
Elderly patients with mantle cell lymphoma (MCL) experienced doubled remission time when they received rituximab as maintenance therapy after responding to induction therapy.The randomised controlled trial involved 564 patients from eight different European countries.
>> http://www.medscape.com/viewarticle/744453?sssdmh=dm1.695145&src=nldne
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu